0.5835
1.27%
-0.0075
시간 외 거래:
.5801
-0.0034
-0.58%
DBV Technologies ADR 주식(DBVT)의 최신 뉴스
DBV Technologies Announces Plan to Implement ADS Ratio Change - GlobeNewswire
GlobeNewswire
DBV Technologies Announces Plan to Implement ADS Ratio Change
GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Start Week Higher - MSN
MSN
DBV Technologies Announces Results of its 2024 Combined General Meeting - WICZ
WICZ
DBV Technologies Announces Results of its 2024 Combined General Meeting - GlobeNewswire
GlobeNewswire
DBV Technologies Announces Results of its 2024 Combined General Meeting
GlobeNewswire Inc.
DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com - MarketBeat
MarketBeat
DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com - Defense World
Defense World
HC Wainwright Lowers DBV Technologies (NASDAQ:DBVT) Price Target to $5.00 - Defense World
Defense World
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Thursday - MSN
MSN
European Equities Traded in the US as American Depositary Receipts Rise Tuesday - MSN
MSN
European Equities Traded in the US as American Depositary Receipts Trend Lower Tuesday - MSN
MSN
DBV Technologies to Participate in Upcoming Investor Conferences - GlobeNewswire
GlobeNewswire
Participation de DBV Technologies aux conférences investisseurs en mai
GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Rebound After Slow Start Tuesday - MSN
MSN
H.C. Wainwright slashes DBV Technologies shares target ahead of crucial Viaskin trial - Investing.com South Africa
Investing.com South Africa
DBV Technologies (NASDAQ:DBVT) PT Lowered to $5.00 - MarketBeat
MarketBeat
DBV Technologies earnings missed by $0.05, revenue fell short of estimates - Investing.com South Africa
Investing.com South Africa
H.C. Wainwright slashes DBV Technologies shares target ahead of crucial Viaskin trial - Investing.com
Investing.com
DBV Technologies (NASDAQ:DBVT) PT Lowered to $5.00 - MarketBeat
MarketBeat
DBV Technologies Reports First Quarter 2024 Financial Results and Business Update - GlobeNewswire
GlobeNewswire
DBV Technologies Reports First Quarter 2024 Financial Results and Business Update
GlobeNewswire Inc.
DBV Technologies Reports First Quarter 2024 Financial Results and Business Update - GlobeNewswire
GlobeNewswire
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - MSN
MSN
DBV Technologies (NASDAQ:DBVT) Receives New Coverage from Analysts at StockNews.com - MarketBeat
MarketBeat
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN
MSN
Assemblée Générale Mixte du 16 mai 2024
GlobeNewswire Inc.
Combined General Meeting of May 16, 2024 - Yahoo Finance
Yahoo Finance
Eosinophilic Esophagitis Pipeline, Clinical Trials, FDA Approvals, and Companies 2024 (Updated) - openPR
openPR
Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024
GlobeNewswire Inc.
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
GlobeNewswire Inc.
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
GlobeNewswire Inc.
DBV Technologies Reports Full Year 2023 Financial Results and Business Update - Yahoo Finance
Yahoo Finance
DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
GlobeNewswire Inc.
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
GlobeNewswire Inc.
DBV Technologies And 2 Other Stocks Under $2 Insiders Are Buying
Benzinga
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
GlobeNewswire Inc.
Roche and Novartis’ Xolair set for FDA priority review in food allergies - Pharmaceutical Technology
Pharmaceutical Technology
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2023
GlobeNewswire Inc.
Down -25.23% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)
Zacks Investment Research
DBV to start supplemental safety trial for peanut allergy patch in Q1 2024 - Clinical Trials Arena
Clinical Trials Arena
Peanut skin patch shows promise in toddlers with allergies - CBS Boston
CBS Boston
Toddlers saw peanut allergies ease after wearing 'peanut patch' in trial - NBC News
NBC News
DBV sets course on regulatory journey for peanut allergy patch - Pharmaceutical Technology
Pharmaceutical Technology
DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in ... - GlobeNewswire
GlobeNewswire
This Immunotherapy Could Be The First to Treat Milk Allergy in Children - Labiotech.eu
Labiotech.eu
DBV Battles Aimmune for Share of Peanut Allergy Treatment Market - Labiotech.eu
Labiotech.eu
DBV Technologies leaps on FDA Viaskin Peanut update news - The Pharma Letter
The Pharma Letter
DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years - GlobeNewswire
GlobeNewswire
Nuts! DBV to peel adhesive (red) tape from allergy bid; stock plunges - BioWorld Online
BioWorld Online
자본화:
|
볼륨(24시간):